← Back to Screener
Anixa Biosciences, Inc. (ANIX)
Price$2.83
Favorite Metrics
Price vs S&P 500 (26W)-37.99%
Price vs S&P 500 (4W)-0.05%
Market Capitalization$94.88M
All Metrics
Book Value / Share (Quarterly)$0.45
P/TBV (Annual)14.95x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.21
Price vs S&P 500 (YTD)-8.73%
Gross Margin (TTM)100.00%
Net Profit Margin (TTM)-1090.48%
EPS (TTM)$-0.32
10-Day Avg Trading Volume0.11M
EPS Excl Extra (TTM)$-0.32
EPS (Annual)$-0.34
ROI (Annual)-72.07%
Gross Margin (Annual)97.00%
Net Profit Margin (5Y Avg)-2904.81%
Cash / Share (Quarterly)$0.42
ROA (Last FY)-67.95%
EBITD / Share (TTM)$-0.34
ROE (5Y Avg)-51.70%
Operating Margin (TTM)-1219.05%
Cash Flow / Share (Annual)$-0.22
P/B Ratio6.29x
P/B Ratio (Quarterly)6.51x
Net Income / Employee (Annual)$-3
EV / Revenue (TTM)444.46x
Net Interest Coverage (TTM)-9.44x
ROA (TTM)-62.53%
EPS Incl Extra (Annual)$-0.34
Current Ratio (Annual)8.08x
Quick Ratio (Quarterly)11.49x
3-Month Avg Trading Volume0.24M
52-Week Price Return10.57%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.26
P/S Ratio (Annual)451.83x
Asset Turnover (Annual)0.01x
52-Week High$5.46
Operating Margin (5Y Avg)-3024.30%
EPS Excl Extra (Annual)$-0.34
Tangible BV CAGR (5Y)36.29%
26-Week Price Return-34.01%
Quick Ratio (Annual)7.71x
13-Week Price Return-7.28%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)12.18x
Enterprise Value$93.337
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)4.92%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.45x
Pretax Margin (Annual)-4728.57%
Cash / Share (Annual)$0.46
3-Month Return Std Dev48.02%
Gross Margin (5Y Avg)88.48%
Net Income / Employee (TTM)$-3
ROE (Last FY)-72.07%
Net Interest Coverage (Annual)-9.44x
EPS Basic Excl Extra (Annual)$-0.34
P/FCF (TTM)20.63x
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.32
Receivables Turnover (Annual)0.00x
ROI (TTM)-65.55%
P/S Ratio (TTM)451.83x
Pretax Margin (5Y Avg)-2941.13%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.26
Price vs S&P 500 (52W)-19.26%
Year-to-Date Return-6.09%
5-Day Price Return6.93%
EPS Normalized (Annual)$-0.34
ROA (5Y Avg)-48.99%
Net Profit Margin (Annual)-4671.90%
Month-to-Date Return13.57%
EBITD / Share (Annual)$-0.36
Operating Margin (Annual)-5243.33%
LT Debt / Equity (Annual)4.72x
ROI (5Y Avg)-51.70%
LT Debt / Equity (Quarterly)11.73x
EPS Basic Excl Extra (TTM)$-0.32
P/TBV (Quarterly)14.95x
P/B Ratio (Annual)8.97x
Inventory Turnover (TTM)0.89x
Pretax Margin (TTM)-1100.00%
Book Value / Share (Annual)$0.46
Price vs S&P 500 (13W)-7.97%
Beta0.64x
P/FCF (Annual)72.43x
Revenue / Share (TTM)$0.00
ROE (TTM)-65.55%
52-Week Low$2.44
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.10
4.10
4.10
4.10
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ANIXAnixa Biosciences, Inc. | 451.83x | — | 100.00% | — | $2.83 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Anixa Biosciences develops cancer vaccines and immunotherapies targeting major oncology indications including breast, ovarian, lung, colon, and prostate cancers. The company operates two primary therapeutic segments: cancer vaccines for treatment and prevention, and CAR-T therapies including lira-cel for ovarian cancer through subsidiary Certainty Therapeutics. Anixa's approach addresses critical unmet needs in oncology through multiple immunotherapy modalities.